Biosimilars

COVID-19

Cataract Surgery

Cataract

Cataract Therapeutics

NeuroOp Guru

The Residency Report

Clinical Diagnosis

Cornea

Dry Eye Awareness

Dry Eye

Gene Therapy

Geographic Atrophy

IOL Advances

Imaging

Glaucoma Awareness

Glaucoma Insights

Therapeutic Glaucoma

Interventional Glaucoma

Ocular Allergy

Ocular Surface Disease

Optic Relief

Optometry

Pediatrics

Pharmacy

Indispensable

Practice Management

Presbyopia

Ptosis

Refractive Surgery

Refractive

Retina

Surgery

Technology

Therapeutics

Understanding Antibiotic Resistance

Workplace

News

All News

Contributors

Money Matters

Media

All Videos

Expert Interviews

Medical World News

Podcasts

Case Based Roundtable Series

Case of the Quarter

EyeView

Grand Rounds

Insights

Rapid Readout

Viewpoints

What’s Your WhEYE?

Conferences

Conference Coverage

Conference Listing

Events

Publications

Digital Edition

Europe Ophthalmology Times

Modern Retina

Supplements and Featured Publications

Partners

Subscribe

Resources

Job Board

Articles

Both 6-month trials were randomized, controlled studies that evaluated PER-001 delivered in a slow-release, dissolvable implant injected intravitreally every 6 months.

PER-001 shows vision restoration in glaucoma and DR in phase 2a trials

The company notes that the workforce reduction is expected to provide annual cash compensation cost savings of approximately $15 million and offsets additional expenses expected based on the accelerated timelines for the 4FRONT clinical trials. 

4DMT accelerating 4D-150 4FRONT phase 3 program, laying off 25% of staff

LumiThera’s PBM is the only device that has demonstrated meaningful vision improvement compared to baseline for people living with early to intermediate dry AMD.

Alcon to acquire LumiThera and its photobiomodulation device for the treatment of dry AMD

Balwantray C. Chauhan, PhD, is the Mathers Professor and Research Director, Departments of Ophthalmology and Visual Science, Medical Neuroscience, and Physiology and Biophysics, at Dalhousie University in Halifax, Nova Scotia, Canada.

At the 2025 International SPECTRALIS Symposium—And Beyond (ISS), Chauhan discussed how two-photon microscopy enables precise, non-invasive monitoring of retinal ganglion cell function in living subjects.

Balwantray C. Chauhan, PhD, explores in vivo functional imaging of single retinal ganglion cells with two-photon imaging

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

About

Advertise

Privacy

Editorial Info

Editorial Board

Terms and Conditions

Contact Us

Do Not Sell My Personal Information

Ophthalmology Times – Clinical Insights for Eye Specialists

Facebook

Instagram

LinkedIn

Spotlight

Clinical

Glaucoma

1rem

Journals

Ophthalmology Times: May/June 2025

Ixo-vec shows sustained efficacy and reduces injection burden through 4 years in clinical trials

 Redefining retinal care: Ixo-vec gene therapy for nAMD enters phase 3

Intracameral tPA can treat fibrinous clots in severe anterior uveitis.

tPA: A (new) tool in the uveitis armamentarium for patient care

Changing demographics and increasing trial complexity present challenges and opportunities.

Expanding access, enhancing research:  The evolving landscape of ophthalmic clinical trials

Timely diagnosis and personalized treatment are key to improving visual outcomes.

Targeted therapies improve care for Demodex blepharitis and OSD

Pathways for better care: When patients and providers move in sync

Deep learning discerns IIH, NAION, and normal eyes using single fundus image.

Artificial intelligence enhances detection of neuro-ophthalmic disorders